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In follicular lymphoma, nonmalignant immune cells are important. Follicular lymphoma depends on CD4þ cells, but
CD8þ cells counteract it. We hypothesized that the presence of follicular lymphoma is associated with higher CD4þ than
CD8þ cell numbers in the tumor microenvironment but not in the immune system. Using ﬂow cytometry, pre-treatment and
follow-up CD4/CD8 ratios were estimated in the bone marrow, blood and lymph nodes of untreated follicular lymphoma
patients in two independent data sets (N1¼121; N2¼166). The ratios were analyzed for their relation with bone marrow
lymphoma involvement. Bone marrows were also investigated with immunohistochemistry. In either data set, the bone marrow
CD4/CD8 ratios were higher in bone marrows involved with lymphoma (P¼0.043 and 0.0002, respectively). The mean CD4/CD8
ratio was 1.0 in uninvolved and 1.4 in involved bone marrows. Also higher in involved bone marrows were CD4/CD56 and
CD3CD25/CD3 ratios. No blood or lymph node ratios differed between bone marrow-negative and -positive patients. Sequential
samples showed increased bone marrow CD4/CD8 ratios in all cases of progression to bone marrow involvement.
Immunohistochemistry showed CD4þ, CD57þ, programmed death-1þ, forkhead box protein 3þ and CD21þ cells
accumulated inside the lymphoma inﬁltrates, whereas CD8þ, CD56þ and CD68þ cells were outside the inﬁltrates.
This study provides evidence in vivo that the microenvironment changes upon follicular lymphoma involvement.
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INTRODUCTION
Investigations of follicular lymphoma lymph nodes have shown
that high levels of CD4þ cells,
1,2 low levels of CD8þ cells,
2- -4
high CD4/CD8 ratios,
2 and more follicular than interfollicular
CD4þ cells
2,5 correlate with inferior clinical outcome. Follicular
lymphoma cells, as their normal counterparts, germinal center B
cells, are supported and protected by signals from CD4þ follicular
helper T cells but counteracted by CD8þ cytotoxic T cells,
according to several in vitro studies.
6- -14
There thus seems to be a vital incentive for follicular lymphoma
to recruit CD4þ cells and to reduce the number of CD8þ cells.
We hypothesized that the presence of follicular lymphoma is
associated with higher CD4þ than CD8þ cell numbers in the
immune microenvironment but not in the immune system.
Using ﬂow cytometry, we analyzed pre-treatment and follow-up
CD4/CD8 ratios in bone marrows, blood and lymph nodes with
respect to bone marrow involvement in two independent data
sets of untreated patients with follicular lymphoma. Bone marrow
involvement, seen in 40--70% of cases, is also an important
adverse factor for outcome,
15 even in the current era of therapy
with the anti-CD20 monoclonal antibody rituximab.
16
MATERIALS AND METHODS
First data set
We ﬁrst constructed a data set of patients treated in Stockholm between
1994 and 2010. Their bone marrows had been sampled at the time of their
original diagnosis of follicular lymphoma at the Department of Pathology,
Karolinska University Hospital, Huddinge, Sweden. Flow cytometry analysis
was routinely performed on all unﬁxed material, as described previously.
4
At least 10000 cells were collected and analyzed. The antibody clones used
for ﬂow cytometry varied over these 16 years. The patients in the ﬁrst data
set were studied according to a protocol approved by the Ethics
Committee in Stockholm. Clinical characteristics were obtained from the
patient ﬁles.
Second data set
The independent second set consisted of other patients who participated
in two similar Nordic Lymphoma Group trials where all patients received
rituximab without chemotherapy (M39035
(ref. 17) and ML16865).
18 Bone
marrows were sampled at trial inclusion, and ﬂow cytometry was
recommended in the trial protocols. The ﬂow cytometry assays at the
participating centers were conducted according to a central protocol, as
reported previously.
18 At least 10000 cells were collected and analyzed.
The CD4, CD8, CD25 and CD56 ﬂow cytometry antibody clones
were chosen according to local routines and, thus, the clones used for
ﬂow cytometry varied between different institutions. These patients were
studied under protocols approved by the Ethics Committee at each
participating center. Clinical characteristics were obtained from case report
forms.
In both the ﬁrst and the second set, every diagnosis of follicular
lymphoma had been ascertained in central pathology reviews of
diagnostic lymph nodes.
4,18 We selected patients in whom the ﬁrst bone
marrow sample had been obtained before any systemic therapy, because
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19,20 A bone
marrow sample consisted of an aspiration (for ﬂow cytometry) and a
biopsy (for morphological diagnosis of bone marrow involvement).
Bone marrow involvement was established on the basis of local pathology
reports of the bone marrow biopsies. All bone marrows (ﬁrst set, N1¼121;
second set, N2¼166; Ntotal¼287) had been analyzed with ﬂow cytometry
enumerations of CD4þ and CD8þ cells and all results were reported
as percentages of events within lymphocyte gate.
The bone marrow CD4/CD8 ratio
Bone marrow involvement in follicular lymphoma is the result of an
invasion by malignant B cells into the tissue. Because the malignant
B cells are counted in ﬂow cytometry assays, the CD4þ and CD8þ cell
percentages will be affected but not the CD4/CD8 ratio, which was
therefore the primary variable. The CD4/CD56 and CD3CD25/CD3 ratios,
when available (n¼158 and 85, respectively), were also analyzed.
Blood and lymph nodes and sequential samples
Blood is seldom involved with follicular lymphoma, while the diagnostic
lymph nodes by deﬁnition are. To investigate whether bone marrow
involvement has an association with distant immune cells in uninvolved
tissue (blood) or involved tissue (lymph nodes), we evaluated all
contemporaneous ﬂow cytometry assays of blood (n¼108) and diagnostic
lymph nodes (n¼169). We also analyzed follow-up bone marrows
(n¼155), including nine cases with simultaneous blood ﬂow cytometry.
Immunohistochemistry
In the ﬁrst set, 47 bone marrow biopsies obtained at diagnosis had
sufﬁcient material for additional stainings. They were reviewed with
additional immunohistochemistry stainings for CD79a (JCB117, Dako,
Glostrup, Denmark), CD20 (L26, Dako), CD21 (2G9, Novocastra, Newcastle,
UK), CD3 (565, Novocastra), CD4 (368, Novocastra), CD57 (NKI, Novocastra),
programmed death-1 (PD-1; AB 52587, Abcam, Cambridge, UK), forkhead
box protein 3 (FOXP3; AB 20034, Abcam), CD8 (C8/144B, Dako), CD56 (1B6,
Novocastra) and CD68 (PG-M1, Dako). The stainings were analyzed without
knowledge of the ﬂow cytometry results.
Statistical analysis
To normalize the ratios, a logarithmic transformation was applied before
statistical testing for association with bone marrow positivity. In univariate
analysis, differences in ratios between patients with and without bone
marrow involvement were estimated with Student’s t-test (for sequential
samples in the same patients the paired t-test was used). Multivariate
analysis was performed with forward stepwise logistic regression. The
multivariate models did not contain any interactions, and they passed
post-estimation controls. Correlations between ratios were estimated with
linear regression. Categoric data were compared using the w
2-test.
All P-values are two-tailed and calculated using Stata 9.2 (StataCorp.
LP, College Station, TX, USA).
RESULTS
Bone marrow CD4/CD8 ratios are signiﬁcantly higher in patients
with bone marrow involvement
Lymphoma involvement of the bone marrow was seen in 52 out
of 121 patients (43%) in the ﬁrst data set and in 92 out of 166
(55%) in the second set, in total in 144 out of 287 (50%). In the ﬁrst
set, the bone marrow CD4/CD8 ratios were signiﬁcantly higher in
patients who had bone marrow involvement than in those who
did not (P¼0.043; Table 1). The ﬁnding was conﬁrmed in the
independent second set (P¼0.0002). In the combined data set,
the mean bone marrow CD4/CD8 ratio was 1.0 in patients without
and 1.4 in patients with bone marrow involvement (overall
P¼0.0002; N¼287). Graphically, the CD4/CD8 ratios showed a
slight general shift to the right in the bone marrow-positive
populations (Figure 1a). Some clinical factors correlated with bone
marrow involvement in either data set (Table 2). The only clinical
factor signiﬁcant in both the ﬁrst and the second set was more
than four involved nodal areas. Multivariate analysis of the bone
marrow CD4/CD8 ratios together with all clinical factors listed in
Table 2 showed that the bone marrow CD4/CD8 ratios (ﬁrst set,
P¼0.034; second set, P¼0.001; overall, P¼0.0003) and more
than four involved nodal areas (ﬁrst set, Po0.0001; second set,
Po0.0001; overall, Po0.0001) were independently associated with
bone marrow involvement. Bone marrow-positive samples also
presented signiﬁcantly higher bone marrow CD4/CD56 ratios
(P¼0.002; n¼158). The mean bone marrow CD4/CD56 ratio was
1.8 in patients without and 2.8 in patients with bone marrow
involvement. The CD3CD25/CD3 ratios were higher in involved
(mean 0.13) than in uninvolved (mean 0.10) bone marrows but the
difference was not signiﬁcant (P¼0.06; n¼85).
Blood and lymph node CD4/CD8 ratios are similar in patients
with and without bone marrow involvement
The CD4/CD8 ratios in blood (mean 1.6) and lymph nodes
(mean 4.5) were similar in patients with and without bone marrow
involvement in either data set as well as in the combined data set
(Table 1). Also equal in bone marrow-positive and -negative
patients were CD4/CD56 ratios in blood (mean 2.6; P¼0.86;
n¼86) and lymph nodes (mean 51.4; P¼0.70; n¼97) as were
CD3CD25/CD3 ratios in blood (mean 0.14; P¼0.25; n¼22) and
lymph nodes (mean 0.23; P¼0.92; n¼62).
Bone marrow and blood CD4/CD8 ratios are closely related
in bone marrow-negative patients but not in bone
marrow-positive patients
In patients without bone marrow involvement, more than half of
the variation of the bone marrow CD4/CD8 ratios could be
explained by the blood CD4/CD8 ratios, and vice versa (R
2¼0.6;
Figure 1b). In bone marrow-positive patients, the bone marrow
and blood CD4/CD8 ratios showed a much weaker association
(R
2¼0.2). The lymph node ratios were entirely unrelated to bone
marrow or blood ratios (data not shown).
Table 1. CD4/CD8 ratios in bone marrow, blood and lymph nodes
Ratio First data set (N1¼121) Second data set (N2¼166)
Overall
(N¼287)
Bone marrow
uninvolved
Bone marrow
involved
P-value Bone marrow
uninvolved
Bone marrow
involved
P-value P-value
Mean SD Mean SD Mean SD Mean SD
Bone marrow CD4/CD8 1.2 0.7 1.7 2.8 0.043 0.9 0.6 1.2 0.8 0.0002 0.0002
Blood CD4/CD8 1.9 1.2 2.2 1.2 0.52 1.5 0.9 1.4 0.8 0.79 0.54
Lymph node CD4/CD8 4.0 2.1 4.7 3.6 0.36 4.5 3.1 4.7 2.5 0.48 0.25
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Blood Cancer Journal & 2012 Macmillan Publishers LimitedSequential samples from bone marrow and blood suggest that
the bone marrow CD4/CD8 ratio increases upon lymphoma
involvement and decreases when the lymphoma disappears
Of the 155 patients with follow-up bone marrow samples,
there were four initially bone marrow-negative patients whose
follow-up bone marrow biopsies showed lymphoma involvement.
This change to bone marrow involvement was accompanied by
an increased bone marrow CD4/CD8 ratio in all four patients, and
thus that more CD4þ than CD8þ cells were recruited (P¼0.035;
Figure 2a). One of these four patients remained untreated but the
other three received rituximab between the ﬁrst and the second
biopsy. Rituximab could affect the T-cell subsets. To control
for this, we investigated the 36 patients who showed no bone
marrow involvement both before and after treatment with
rituximab and found no difference between CD4/CD8 ratios in
the ﬁrst and second bone marrow biopsies (mean 1.0 at both time
points; Figure 2b). Furthermore, in the total of 125 patients whose
bone marrows were analyzed before and after rituximab therapy,
there was no change in the bone marrow CD4/CD8 ratios
(mean 1.2 at both time points). Bone marrow and blood were
simultaneously analyzed in nine patients both before and after
rituximab therapy; seven were initially bone marrow positive and
two were negative. All nine patients were bone marrow negative
at follow-up sampling. Six of the seven patients who changed
from involvement to no involvement of the bone marrow had a
marked decrease of the CD4/CD8 ratios in bone marrow
(P¼0.023; Figure 2c) but not in blood (P¼0.83; Figure 2d).
However, the decrease in bone marrow CD4/CD8 ratios was not
signiﬁcant when analyzing all 65 bone marrows that turned from
positive to negative (P¼0.22), although the mean changed from
1.5 to 1.1.
Immunohistochemistry analysis of involved bone marrows
reveals higher frequencies and altered topographic distributions
of T-cell subsets and follicular dendritic cells
In every investigated case, the archival report whether the bone
marrow was involved with lymphoma (n¼21) or not (n¼26) was
Table 2. Clinical characteristics
Characteristic
First data set (N1¼121) Second data set (N2¼166) Overall
(N¼287)
Bone marrow
uninvolved
(N¼69)
Bone marrow
involved
(N¼52)
P-value Bone marrow
uninvolved
(N¼74)
Bone marrow
involved
(N¼92)
P-value P-value
Histological subtype- - -% 0.69 0.55 0.92
Grade 1 29 29 53 48
Grade 2 55 50 43 48
Grade 3A 16 21 4 4
Male sex- - -% 49 56 0.48 54 49 0.51 0.95
Age 460 years- --% 52 37 0.087 35 29 0.43 0.046
LDH elevated- - -% 33 31 0.77 20 36 0.028 0.17
Hemoglobin o12 g/dl- - -% 3 8 0.23 14 24 0.091 0.016
44 nodal areas involved- - -% 13 56 o0.0001 35 71 o0.0001 o0.0001
B symptoms- - -% 14 33 0.017 23 24 0.89 0.099
Abbreviation: LDH, lactate dehydrogenase.
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Figure 1. Bone marrow CD4/CD8 ratios and their correlations to blood CD4/CD8 ratios stratiﬁed by bone marrow lymphoma involvement.
(a) Shows histograms of the bone marrow CD4/CD8 ratios in the ﬁrst (above) and second (below) data sets. Black bars show the distribution
of CD4/CD8 ratios in bone marrows involved with lymphoma and gray-striped transparent bars CD4/CD8 ratios in those uninvolved with
lymphoma. (b) Shows the correlations between bone marrow and blood CD4/CD8 ratios. In patients without bone marrow lymphoma
involvement (gray dots and gray ﬁtted line), there was a general, systemic congruence between the two types of tissue. In patients with bone
marrow involvement (black crosses and black ﬁtted line), there was markedly less congruence.
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involvement showed invariably a sparse, diffuse distribution of
cells positive for CD3, CD4, CD8, CD20, CD56, CD57, CD79a, FOXP3
and CD68; cells positive for CD21 were absent and those positive
for PD-1 were extremely rare (Figure 3). In 16 out of the 21
biopsies positive for follicular lymphoma, CD21þ follicular
dendritic cell networks surrounded the lymphoma cells, but a
remarkable ﬁnding was that in ﬁve cases the follicular lympoma
inﬁltrates lacked CD21þ networks. Furthermore, some biopsies
contained a mix of CD21þ and CD21- lymphoma inﬁltrates
(Figure 3). The CD4þ cells homed to the follicular lymphoma
inﬁltrates in all cases, as did FOXP3þ and CD57þ cells. PD-1þ
cells resided almost exclusively in the lymphoma inﬁltrates, usually
in the central area of them. In the involved bone marrows,
the CD8þ cells were few, found outside or in the periphery
of the inﬁltrates, or sometimes sparsely throughout the biopsy.
The CD68þ and CD56þ cells were diffusely distributed outside
the lymphoma inﬁltrates but the areas with lymphoma inﬁltration
contained very few CD68þ and CD56þ cells (Data not shown).
Increasing bone marrow involvement correlates with higher
bone marrow CD4/CD8 ratios
At review, the percentage of lymphoma involvement in the
involved bone marrow biopsies was estimated. There was a
positive correlation between increasing areas of lymphoma in
the biopsy and higher bone marrow CD4/CD8 (P¼0.010) and
CD4/CD56 (P¼0.043) ratios in ﬂow cytometry. The median
percentage of bone marrow involvement was 15%. In bone
marrows with o15% lymphoma inﬁltration, the mean bone
marrow CD4/CD8 ratio was 1.2, while in those with X15%
lymphoma, the mean was 2.9. The corresponding ﬁgures for
CD4/CD56 were 2.1 and 3.6.
DISCUSSION
This report shows that follicular lymphoma cells in the bone
marrow alter the local immune microenvironment. Using ﬂow
cytometry in two independent data sets of untreated patients, we
found increased bone marrow CD4/CD8 ratios in bone marrows
involved with follicular lymphoma. The blood and lymph node
CD4/CD8 ratios did not change with bone marrow involvement,
suggesting that the immunomodulating effect of follicular
lymphoma is locally restricted. We also examined sequential
samples of patients and found that initially bone marrow-negative
patients who later progressed to bone marrow involvement
showed accompanying increases in their bone marrow CD4/CD8
ratios. This did not appear to be an effect from interceding
rituximab, because rituximab did not change the CD4/CD8 ratios
in patients whose disease did not progress to bone marrow
involvement.
Using ﬂow cytometry, we investigated T-cell subsets positive for
CD4, CD8 and CD25, as well as natural killer (NK) cells positive for
CD56. We found that follicular lymphoma is connected with
relatively more CD4þ T cells than CD8þ T cells and CD56þ NK
cells. There was also a trend for larger proportions of T cells
positive for CD25 in involved bone marrows. To further investigate
these ﬁndings, we examined a fraction of the bone marrows using
immunohistochemistry. CD4þ cells were abundant within
follicular lymphoma inﬁltrates. The results were similar for
FOXP3þ (regulatory T) and CD57þ T cells. PD-1þ cells were
detected in the involved bone marrows, always inside the
lymphoma inﬁltrates, but were virtually absent in lymphoma-
negative marrows. CD21þ networks were found in 76% of the
lymphoma-involved bone marrows but in none of those without
lymphoma. CD8þ cells were scarce and located in the periphery
of the lymphoma inﬁltrates or diffusely distributed outside them.
CD56þ NK cells and CD68þ macrophages were located outside
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Figure 2. CD4/CD8 changes in sequential samples. Dashed lines
represent patients with initially no bone marrow lymphoma
involvement and solid lines those with initial involvement. The
y scales are logarithmic. (a) Shows how bone marrow CD4/CD8 ratios
increased in all four bone marrow-negative patients who progressed
to bone marrow involvement. Three of these four patients received
rituximab in the meantime, but (b) demonstrates that rituximab
therapy did not induce bone-marrow CD4/CD8 changes in patients
who retained bone marrows free from lymphoma. (c, d) Show the
nine patients with complete sequential samples of bone marrow
and blood CD4/CD8 ratios. The numbers represent patient identity.
All nine received rituximab between samples. Seven patients
(solid lines) cleared their marrows from lymphoma, and six of these
also showed decreased bone marrow CD4/CD8 ratios (c), but
there was no similar tendency in the comparable blood CD4/CD8
ratios of which two decreased, two were stable and three
increased (d).
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Figure 3. Immunohistochemistry of bone marrows. All investigated bone marrows without follicular lymphoma involvement had the same
appearance (left-most column, Uninvolved A), showing few and scattered cells positive for CD20, CD4, CD57, FOXP3 and CD8. There are no cells
positive for CD21 or PD-1. This bone marrow is from the patient who later progressed to bone marrow involvement (Involved A), without any
interceding therapy. The CD20 staining in the later biopsy shows a moderate inﬁltration of lymphoma cells. There are no accompanying CD21þ
follicular dendritic cells. CD4þ and CD57þ T cells are mostly located in the inﬁltrates. PD-1þ T cells are exclusively found in the inﬁltrates and
also FOXP3þ cells have homed there. There are some CD8þ cytotoxic T cells in the periphery of the inﬁltrates. Involved B is a bone marrow
with heavy involvement of follicular lymphoma. Two involved areas (the red and yellow squares) have been examined in large magniﬁcation.
CD21þ follicular dendritic cell networks are seen in one area, but not in the other, suggesting different stromal cells’ support in the same
specimen. The distributions of cells positive for CD4, CD57, PD-1 and CD8 seem to differ between the two areas. In both areas, FOXP3þ showed a
perifollicular pattern. Involved C shows peritrabecular follicular lymphoma inﬁltrates. There is a CD21þ follicular dendritic cell network and
an aggregation of CD4þ, CD57þ,P D - 1þ and FOXP3þ T cells.
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Blood Cancer Journal & 2012 Macmillan Publishers Limitedthe inﬁltrates. These ﬁndings are similar to the microenvironment
of follicular lymphoma lymph nodes. It appears that follicular
lymphoma brings its entourage to the involved tissue.
21
Multiple mechanisms, none of which are mutually exclusive,
may be invoked to explain why follicular lymphoma needs its
entourage. Follicular lymphoma cells, such as normal germinal
center B cells, seem to be dependent on other cells in the
microenvironment. Follicular helper T cells express CD40 ligand,
which interacts with CD40 on malignant and nonmalignant B cells
and protects them from apoptosis.
6- -9Follicular helper T cells also
secrete interleukin (IL)-4 at very high levels, promoting
survival and proliferation of follicular lymphoma cells.
10- -12 The
IL-4 receptor gene is upregulated in follicular lymphoma cells.
11,22
IL-4 inhibits CD8þ cells.
23 Likewise, both follicular lymphoma and
germinal center B cells are supported by follicular dendritic
cells.
24- -26 In this report, most, but not all, investigated lymphoma-
inﬁltrated bone marrows contained CD21þ follicular dendritic
cell networks. The CD21þ follicular dendritic cells are normally
alien to the bone marrow. Migration of follicular dendritic cells
from lymph tissue is unlikely. Rather, the follicular lymphoma cells
induce local mesenchymal precursors to differentiate into CD21þ
follicular dendritic cells.
27,28 Bone marrow mesenchymal cells
have also been shown to nurse follicular lymphoma cells,
13,29,30
and could possibly substitute for CD21þ follicular dendritic cell
networks (Figure 3). The stromal cells’ growth-promoting effects
on follicular lymphoma cells are overruled by interferon-g, which is
mainly produced by CD8þ cytotoxic T cells and CD56þ NK cells
within normal and malignant lymphoid organs.
13 Interferon-g also
inhibits B-cell migration,
31 plausibly preventing the spread
of follicular lymphoma. Furthermore, interferon-g modulates
the development of naı ¨ve CD4þ T cells to helper1 T cells.
32
The balance between helper1--cytotoxic T-cell cytokines on one
hand and helper2--follicular helper T-cell cytokines on the other is
probably skewed in follicular lymphoma. IL-4 is the only cytokine
that is found in higher levels in follicular lymphoma than in
reactive follicular hyperplastic lymph nodes.
33
Follicular lymphoma cells, follicular helper T cells, follicular
dendritic cells and bone marrow mesenchymal stem cells can
secrete C--X--C motif chemokine 13 (CXCL13), which attracts
C--X--C chemokine receptor type 5 (CXCR5)-positive follicular
helper T and follicular lymphoma cells to the lymphoma area.
34- -36
B cells express membrane lymphotoxin a1b2 and tumor necrosis
factor to stimulate CXCL13 production in mesenchymal cells.
13
A subset of CXCR5þCD4þ follicular helper T cells is positive for
PD-1, and we found PD-1þ cells exclusively in the lymphoma
inﬁltrates. These CXCR5þCD4þ T cells will home to the follicular
lymphoma inﬁltrate and contribute to an increased production of
CXCL13 that will attract yet more CXCR5þ cells. Subsequently,
this local aggregation of IL-4 secretors will further perturb the
microenvironment, including a skewing of the differentiation of
naı ¨ve CD4þ cells to the production of more B-cell helpers and an
inhibition of the CD8þ cells. We also showed that regulatory
T cells were prevalent in the lymphoma inﬁltrates, concurring with
the results of an in vitro study, which reported that follicular
lymphoma cells skew the microenvironment in favor of more
regulatory T cells.
37 It has experimentally been shown that
regulatory T cells attenuate other T cells in the follicular lymphoma
microenvironment.
38- -40 It has also been demonstrated that
follicular lymphoma cells induce dysfunctions in neighboring
normal T cells, by reducing their ability to form F-actin immune
synapses.
41 Our ﬁndings also agree with a recent study, which
showed that there are more CXCR5þ (especially
CXCR5þCD25þCD57þ) T cells in follicular lymphoma nodes
than in normal lymph nodes, but the authors also reported
that the remaining helper1 T cells in the tumors should retain
their intrinsic ability to elicit anti-tumor speciﬁc responses.
42
A ‘vaccinal effect’
43,44 might explain why the prognostic impact
of CD4 cells is reversed by rituximab.
18
Normally, the approximate mean CD4/CD8 ratio in bone
marrow is 1.0,
45 in blood 1.5,
46 and in cadaverous normal lymph
nodes 3.3.
47 In the present study, the mean CD4/CD8 ratio was
normal (1.0) in bone marrows without lymphoma involvement but
high (1.4) in bone marrows with lymphoma. The mean blood
CD4/CD8 ratios in bone marrow-negative and -positive patients
were similar, 1.53 and 1.57, respectively. The lymph node CD4/CD8
ratios were high, regardless of the distant bone marrow
status (Table 1). This is consistent with the hypothesis that
follicular lymphoma exerts a local rather than a systemic inﬂuence
on immune cells. When we compared CD4/CD8 ratios in blood
and negative bone marrows, we found that they were closely
related (R
2¼0.6; Figure 1b) but markedly less so when the bone
marrow was involved with lymphoma (R
2¼0.2). The residual
squared correlation coefﬁcient of 0.2 and the CD4/CD8 ratios’
modest shift to the right (Figure 1a) in bone marrow-positive
cases are explained by the parts of the bone marrows, which
remained free from lymphoma. In these parts of the marrows
there is no follicular lymphoma microenvironment and the
systemic, host-speciﬁc immune-cell balances are intact (Figure 3).
Indeed, the bone marrow CD4/CD8 ratios increased with the
degree of follicular lymphoma involvement. Another explanation
for the residual correlation between CD4/CD8 in blood and
involved marrows is an inherent weakness of the bone marrow
sampling method: aspiration will always dilute the marrow
with peripheral blood. The CD4/CD8 ratios in normal bone
marrows are lower if ﬂow cytometry is conducted on biopsies
instead of aspirates (mean 0.6 instead of 1.0).
45 However,
aspiration for ﬂow cytometry is the sole method in clinical and
research use and the dilution of the bone marrow cell suspension
by peripheral blood would only slightly decrease the signiﬁcant
differences reported here, and would not lead to false-positive
results.
Our study suggests that the microenvironment of the bone
marrow changes in patients who progress to bone marrow
involvement. This conclusion is, however, based on only four bone
marrow-negative patients who later progressed to bone marrow
involvement (Figure 2). The ﬁndings give some corroboration to
the concept that follicular lymphoma changes its microenviron-
ment, rather than the idea that host-speciﬁc factors in the bone
marrow will make it more or less prone to being invaded. Other
limitations to this study exist. This report focused on the CD4/CD8
ratio, an established assessment of the balance between the two
major T-cell subsets, to show that follicular lymphoma alters the
local microenvironment. Our data on the CD4/CD8 ratio provide
only a small fraction of the full picture, because CD4þ and CD8þ
cells are but two of many factors, which would be altered by the
lymphoma, as suggested by the immunohistochemistry ﬁndings
and by the CD4/CD56 and CD3CD25/CD3 ratios, and also by
previous studies. However, a strength of this study is the large
number of untreated patients in two independent data sets with
sequential samples. Another strength is that the outcome variable
(involved and uninvolved bone marrow) could be investigated
exclusively in follicular lymphoma patients why we did not have to
introduce bias by comparing tissues in patients and healthy
controls. This allows us to conclude that follicular lymphoma is
associated with, and probably causes, a local change of the
microenvironment, as demonstrated with the CD4/CD8 and
CD4/CD56 ratios. We present the ﬁrst evidence in vivo that
follicular lymphoma induces changes in its microenvironment,
changes that are presumably vital for its persistence in the
affected tissue. Identifying and blocking the mechanisms with
which follicular lymphoma modulates the microenvironment
could be of great clinical beneﬁt.
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